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Three types of nonhemolytic unconjugated hy-
perbilirubinemia have been classified according to
their clinical severity, Crigler-Najjar syndrome type
1 (CN-1: severe, serum bilirubin 340–850 μmol/L)
and type 2 (CN-2: moderate, serum bilirubin
85–340 μmol/L), and Gilbert’s syndrome (mild,
serum bilirubin normal to 85 μmol/L). These
three diseases, reported in 1992, 1993 and 1995,
respectively, are caused by a defect in UDP-
glucuronosyltransferase 1A1 (UGT1A1) because
glucuronidation is essential for biliary elimination
of bilirubin, and UGT1A1 is the only physiolo-
gically relevant isoform in bilirubin glucuroni-
dation.1 Single nucleotide polymorphism may
alter the activity of UGT1A1, and such activities
are absolutely absent, about 10%, and about
30% of normal in patients with CN-1, CN-2, and
Gilbert’s syndromes, respectively.1,2 Unlike CN-1,
tkernicterus is rare and phenobarbital treatmen
results in induction of residual UGT1A1 activity,
with consequent reduction of bilirubin concen-
trations > 25% in CN-2 patients.1,3
The results of some studies showed that all CN
patients carried mutations (variations) within the
coding region of the UGT1A1 gene.1–11 Recently,
we and other authors discovered that, compared to
gCaucasians, the variation rate within the codin
region of the UGT1A1 gene is much higher in
Asians.4,5,12 These findings may indicate that the
prevalence of CN in Asians is higher than in
Caucasians (1 per million).1 yHowever, the onl
treport of CN from Taiwan was in a CN-2 patien
with a novel compound heterozygous variation
(heterozygous C > T at nucleotide 625 plus het-
erozygous G deletion at nucleotide 1186) of the
UGT1A1 gene.6 Two Chinese patients with CN-1
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involving a homozygous nonsense mutation
(R341X) and a novel homozygous nonsense muta-
tion (C >T at nucleotide 715) of the UGT1A1 gene
have also been reported.7,8 Here, we report three
variations in the UGT1A1 gene in one Indian pa-
tient born in Singapore and two Taiwanese CN-2
patients. Two of the three mutations are novel,
with the mutation in the remaining Taiwanese
patient similar to that previously determined for
Japanese CN-2 patients.1,4,5
Methods
The first patient was a 7-year-old Indian girl who
was born full-term in Singapore in 1998. Severe
hyperbilirubinemia was diagnosed on the 4th day
of life. She was the only child of consanguineous
parents. Medical records showed a peak total bili-
rubin of 491 μmol/L, with a conjugated bilirubin
level of 5.1 μmol/L at 1 month after birth. She was
severely icteric without hepatosplenomegaly. The
results of other liver function tests, glucose-
6-phosphate dehydrogenase (G6PD) activity and
hematology tests were normal. Immunologic
tests for hepatitis A, B and C were negative. Serum
bilirubin was reduced to a minimal level of 115
μmol/L at 2 months of life after phototherapy
treatment. In the nursery, she spent 10–14 hours
a day sleeping under a phototherapy light and
showed good intellectual development. Pheno-
barbital treatment was given for 1 week, but serum
bilirubin level was not apparently different from
when she was being treated with phototherapy
only, so this drug therapy was discontinued.
The second patient was a 21-year-old Taiwanese
woman with a history of severe hyperbilirubine-
mia since early childhood. Examination revealed
deep yellow skin and yellow irises. The results 
of other liver function tests, G6PD activity and
hematology tests were normal. Hepatitis B sur-
face antigen (HBsAg) and anti-hepatitis C anti-
body (anti-HCV) were negative. Analysis of a
blood specimen for UGT1A1 gene analysis re-
vealed serum bilirubin level of 217 μmol/L 
per 20.5 μmol/L (total/conjugated). Phenobarbital
therapy led to a decreased serum bilirubin con-
centration (110 μmol/L) 10 days later.
The third patient was a 28-year-old Taiwanese
woman with a history of severe hyperbilirubine-
tmia since infancy. At the time of presentation a
our clinic and UGT1A1 gene analysis, serum biliru-
bin level was 173 μmol/L per 18 μmol/L (total/
conjugated) and alanine aminotransferase was
slightly elevated (45 IU/L; normal, <35). Deep
yellow skin and yellow irises were noted. G6PD
gactivity and hematology tests were normal. HBsA
and anti-HCV antibody tests were negative. Pheno-
barbital treatment was given and total serum biliru-
bin level was reduced to 103 μmol/L 2 weeks later.
The Blood DNA Isolation Kit (Maxim Biotech
Inc., San Francisco, CA, USA) was used to isolate
total genomic DNA from whole blood cells of all
three patients after obtaining written consent. The
promoter area of the UGT1A1 gene, exons 1–4, the
coding region of exon 5, and their flanking in-
tronic regions were amplified by polymerase chain
reaction (PCR) using the primers as described
previously.12
Results
The PCR results for the UGT1A1  gene showed
a homozygous T > A substitution at nucleotide
479 in exon 1 in the Indian girl. No other variation
was detected in the UGT1A1 gene. Theoretically,
the UGT1A1 enzyme in this girl is Val160Glu.
A heterozygous T > A substitution at nucleotide
479 was found in the UGT1A1 rgene of both he
parents. The PCR product for the UGT1A1 gene
showed a homozygous A>G substitution at nu-
cleotide 610 in exon 1 in the first Taiwanese patient.
No other variation was detected in her UGT1A1
gene. Theoretically, the UGT1A1 enzyme is Met204
Val in this patient. The PCR results for the
UGT1A1 tgene in the second Taiwanese patien
indicated that there was a homozygous T > G sub-
stitution at nucleotide 1456 in exon 5 plus a het-
erozygous G > A substitution at nucleotide 211 in
exon 1. No other variation in the UGT1A1 gene
was found. Theoretically, the UGT1A1 enzyme in
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Table. Reported genetic defects in Crigler-Najjar syndrome type 2
Nucleotide change Amino acid substitution Reference Origin/patients (n)
44T > G Leu15Arg 1 Holland/2
111C > A, 1207C > T Pro34Gln, Arg403Cys 11 Italy/1
211G > A, 1456T > G Gly71Arg, Tyr486Asp 1, 4 Japan/6
211G > A/normal, 1456T > G Gly71Arg /normal, Tyr486Asp This report Taiwan/1
479T > A Val160Glu This report India/1
508–510 del TTC Phe170 del 11 Italy/1
524T > A Leu175Gln 1 Holland /1
524T > A/973 del G Leu175Gln/frameshift 1 Holland /1
576C > G, 1130G > T, 6/7 Tyr192Stop, Gly377Val 11 Italy/1
610A > G Met204Val This report Taiwan/1
625C > T Arg209Trp 1 Holland /1,
4 Japan/1
625C > T/1186 del G Arg209Trp/frameshift 6 Taiwan/1
674T > G, 717–718 del AG, 7/7 Val225Gly, frameshift 9 Italy/1
674T > G/722–723 del AG Val225Gly/frameshift 1 America/1
674T > G, 878–890 del, 6/7 Val225Gly, Tyr293Leu, frameshift 11 Italy/1
674T > G, 1130G>T, 7/7 Val225Gly, Gly377Val 11 Italy/1
686C > A/normal, 7/7 Pro229Gln/normal 4 Japan/1
717–718 del AG, 1381T > C, 6/7 Frameshift, Trp461Arg 11 Italy/1
865–1G > A, 1007G > T, 7/7 Splicing, Arg336Leu 11 Italy/1
877T > A, 878–890 del,  Tyr293Met, frameshift,
1060T > C, 6/7 Trp354Arg 11 Italy/1
928A > G, 1292T > C Met310Val, Ile431Thr 3 Africa/1
991C > T/normal Gln331Stop/normal 1 Japan/1
992A > G Gln331Arg 1 Ireland/1
1006C > T, 1130G > T Arg336Trp, Gly377Val 11 Italy/1
1006C > T, 1304+1G > T, 6/7 Arg336Trp, splicing 11 Italy/1
1213A > G, 8/8 Asn400Asp 10 Morocco/1
1391A > C/normal, 7/7 Glu464Ala/normal 1 America/1
1433C > A, 7/7 Ala478Asp 11 Italy/1
1456 T > G Tyr486Asp 1, 5 Japan/5
6/7, 7/7 and 8/8 indicate A(TA)6TAA/A(TA)7TAA, A(TA)7TAA/A(TA)7TAA and A(TA)8TAA/A(TA)8TAA instead of A(TA)6TAA/A(TA)6TAA
in the promoter area of the UGT1A1 gene, respectively.
this patient is Tyr486Asp and half of the enzyme
is Gly71Arg.
Discussion
Our review of previous reports indicate that the
homozygous 479T >A (Val160Glu) and the homo-
zygous 610A > G (Met204Val) variations of the first
and second CN-2 patients in this report are novel
mutations. The compound variation of heterozy-
gous 211G>A (Gly71Arg/normal) and homozygous
1456T > G (Tyr486 tAsp) in our third CN-2 patien
is not a new finding as homozygous 1456T > G
(Tyr486Asp) and double homozygous 211G > A
plus 1456T>G variations (Gly71Arg plus Tyr486Asp)
have previously been reported in Japanese CN-2
patients.1,4,5 A previous in vitro tstudy found tha
the UGT1A1 enzyme activity of the homozygous
Tyr486Asp model was 7.6 ± t0.5% of normal, a
the level necessary for CN-2.2 tThat finding migh
rexplain the highly elevated bilirubin value in ou
third CN-2 patient. Although patients with CN-2
are distinguished from those with CN-1 by a
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response to either phenobarbital treatment or
phototherapy, phenobarbital treatment some-
times has to be repeated several times to success-
fully reduce serum bilirubin levels in CN-2
patients.1,3 Since the serum bilirubin level in the
first patient of this report was reduced after pho-
totherapy, the diagnosis of CN-2 as opposed to
CN-1 is suggested. Repeat phenobarbital treat-
ment for this patient, and the measurement of
UGT1A1 enzyme activity in this patient and the
second CN-2 patient in this report were indi-
cated but not performed during follow-up.
Including our patients, at least 40 CN-2 cases
with confirmed mutations (variations) in the
UGT1A1 gene have now been reported (Table):
18 Asians, 20 Caucasians, and two Africans.
Since the prevalence of CN in Asians may be
higher than in Caucasians, and the results of 
recent research showed that variation of the
UGT1A1 gene is the predominant hereditary de-
fect in Taiwanese patients with unconjugated hy-
perbilirubinemia,6,13–15 more Taiwanese patients
with CN as well as mutant (variant) UGT1A1
gene are likely to be found in the future.
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